NHL
MCID: LYM115
MIFTS: 63

Lymphoma, Non-Hodgkin (NHL) malady

Categories: Genetic diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Lymphoma, Non-Hodgkin

Aliases & Descriptions for Lymphoma, Non-Hodgkin:

Name: Lymphoma, Non-Hodgkin 54 24 13 38 69
Non-Hodgkin Lymphoma 38 12 24 29 14
Familial Non-Hodgkin Lymphoma 24 66
Nhl 24 66
Lymphoma, Non-Hodgkin, Somatic 54
Lymphoma, Follicular, Somatic 54
Lymphoma Non-Hodgkins 52

Classifications:



External Ids:

OMIM 54 605027
Disease Ontology 12 DOID:0060060
MedGen 40 C0024305
ICD10 33 C85.7

Summaries for Lymphoma, Non-Hodgkin

UniProtKB/Swiss-Prot : 66 Familial non-Hodgkin lymphoma: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

MalaCards based summary : Lymphoma, Non-Hodgkin, also known as non-hodgkin lymphoma, is related to non-hodgkin lymphoma, during pregnancy and non-hodgkin lymphoma, childhood, and has symptoms including lymphoma An important gene associated with Lymphoma, Non-Hodgkin is CASP10 (Caspase 10), and among its related pathways/superpathways are IL-2 Pathway and Toll-like Receptor Signaling Pathway. The drugs Bexxar and Intron A have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Disease Ontology : 12 A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.

Wikipedia : 71 Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except... more...

Description from OMIM: 605027

Related Diseases for Lymphoma, Non-Hodgkin

Diseases related to Lymphoma, Non-Hodgkin via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Related Disease Score Top Affiliating Genes
1 non-hodgkin lymphoma, during pregnancy 12.2
2 non-hodgkin lymphoma, childhood 12.1
3 lymphoma 11.7
4 mantle cell lymphoma 11.5
5 reticulosarcoma 11.1
6 lymphoma, gastric non hodgkins type 11.1
7 prader-willi syndrome due to paternal deletion of 15q11q13 type 1 10.5 BCL10 IRF4 MALT1
8 joubert syndrome 18 10.5 CASP10 FAS IL10 PRF1 PTPRC
9 autosomal dominant robinow syndrome 3 10.5 CASP10 FAS IL10 PTPRC
10 parotitis 10.5 CCND1 CD5 MALT1
11 congenital sucrase-isomaltase deficiency with starch and lactose intolerance 10.5 ALK IRF4 NPM1 PTPRC
12 uterine ligament endometrioid adenocarcinoma 10.5 CCND1 CD5 PAX5
13 cecum adenoma 10.5 ALK BCL2 CCND1 NPM1
14 lip cancer 10.5 ALK BCL2 NPM1 PAX5 PTPRC
15 barnicoat baraitser syndrome 10.5 CD19 CD5 MS4A1 MYC
16 theileriasis 10.5 CCND1 CD5 MYC PTPRC
17 subacute delirium 10.5 ALK PAX5 PTPRC
18 macrogyria, pseudobulbar palsy and mental retardation 10.5 ALK FAS NPM1
19 estrogen-receptor negative breast cancer 10.5 ALK CD5 MYC NPM1 PTPRC
20 basal ganglia disease 10.5 CD19 CD5 MALT1 PAX5
21 pyloric antrum cancer 10.5 BCL10 BCL2 MALT1
22 microcystic adenoma 10.5 BCL10 BCL2 CCND1 CD5 IRF4 MALT1
23 aortic arch interruption 10.5 ALK NPM1 PAX5 PTPRC
24 penile disease 10.5 ALK CD19 CD5 IRF4 PTPRC
25 gingival recession 10.5 BCL2 CCND1 IRF4 MS4A1 MYC
26 mesothelioma, somatic 10.5 BCL10 BCL2 CCND1 CD5 IRF4 MALT1
27 degenerative myopia 10.5 CD19 CD5 PAX5
28 melanoma metastasis 10.5 BCL2 CCND1 CD19 CD5 MYC
29 childhood brain stem glioma 10.4 CCND1 CD5 PAX5
30 extragonadal seminoma 10.4 ALK CD5 MYC
31 hereditary ataxia 10.4 CD5 FAS IL10 PRF1
32 ritscher-schinzel syndrome 10.4 FAS MS4A1 MYC PAX5
33 neurofibromatosis 10.4 NPM1 PAX5 PTPRC
34 cutis laxa, autosomal recessive, type ib 10.4 CCND1 CD19 IRF4 MYC PTPRC
35 duodenal ulcer 10.4 CD5 IRF4 MYC
36 male infertility 10.4 BCL2 CCND1
37 ectodermal dysplasia 10.4 ALK BCL10 BCL2 CCND1 CD5 IRF4
38 ethmoid sinus schneiderian papilloma 10.4 CD19 MYC PTPRC
39 bladder disease 10.4 BCL10 BCL2 CCND1 CD5 IRF4 MALT1
40 carnitine-acylcarnitine translocase deficiency 10.4 ALK BCL2 BRAF CASP10 FAS IRF4
41 systemic mastocytosis 10.4 CD5 MALT1 PAX5
42 rhabdomyosarcoma 10.4 IL10 MALT1 PAX5
43 chronic venous leg ulcers 10.4 BCL10 BCL2 CCND1 CD19 CD5 FAS
44 marantic endocarditis 10.4 ALK BCL10 BCL2 CASP10 CCND1 FAS
45 rubella panencephalitis 10.4 BCL2 MALT1
46 seminal vesicle chronic gonorrhea 10.4 CCND1 CD5 MYC
47 congestive heart failure 10.4 CD19 FAS IL10 MS4A1
48 hodgkin lymphoma 10.4
49 pituitary carcinoma 10.3 CCND1 FAS MYC
50 hyperphosphatasia with mental retardation syndrome 2 10.3 CD19 MYC PAX5

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin:



Diseases related to Lymphoma, Non-Hodgkin

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin

Clinical features from OMIM:

605027

Human phenotypes related to Lymphoma, Non-Hodgkin:

32
id Description HPO Frequency HPO Source Accession
1 lymphoma 32 HP:0002665

GenomeRNAi Phenotypes related to Lymphoma, Non-Hodgkin according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.25 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.25 BCL2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.25 IL10
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.25 BCL2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.25 BCL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.25 IL10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.25 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.25 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.25 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.25 CCND1 IL10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.25 BCL2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.25 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.25 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.25 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.25 CCND1 BCL2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.25 BCL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.25 IL10
18 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.25 BCL2 CCND1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.25 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.25 CCND1 IL10 BCL2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.25 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.25 CCND1 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.25 CCND1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.25 BCL2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.25 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.25 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.25 BCL2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.25 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.25 IL10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.25 BCL2 IL10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.25 BCL2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.25 BCL2
33 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.81 FAS IL10 MALT1 RAD54B RAD54L BCL10
34 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.81 FAS IL10 MALT1 MYC RAD54B RAD54L

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.45 FAS IL10 IRF4 MALT1 MS4A1 MYC
2 cellular MP:0005384 10.4 BCL10 BCL2 BRAF CCND1 CD19 FAS
3 immune system MP:0005387 10.39 CD19 CD5 FAS IL10 IRF4 MALT1
4 growth/size/body region MP:0005378 10.29 ALK BCL2 BRAF CCND1 CD19 FAS
5 homeostasis/metabolism MP:0005376 10.26 ALK BCL2 BRAF CCND1 CD19 FAS
6 mortality/aging MP:0010768 10.24 ALK BCL10 BCL2 BRAF CCND1 CD19
7 endocrine/exocrine gland MP:0005379 10.22 ALK BCL10 BCL2 BRAF CCND1 FAS
8 integument MP:0010771 10.17 FAS IL10 MYC NPM1 PRF1 ALK
9 digestive/alimentary MP:0005381 10.14 BCL2 BRAF CCND1 CD19 FAS IL10
10 neoplasm MP:0002006 10.13 ALK BCL2 BRAF CCND1 CD19 FAS
11 nervous system MP:0003631 10.1 ALK BCL10 BCL2 BRAF CCND1 CD19
12 craniofacial MP:0005382 10.09 BCL2 BRAF CCND1 FAS IL10 MYC
13 liver/biliary system MP:0005370 10.01 BRAF CD19 FAS IL10 MYC NPM1
14 normal MP:0002873 9.85 PTPRC BRAF CCND1 CD19 CD5 FAS
15 pigmentation MP:0001186 9.35 BRAF FAS MYC ALK BCL2
16 respiratory system MP:0005388 9.17 ALK BCL2 BRAF CCND1 FAS IL10

Drugs & Therapeutics for Lymphoma, Non-Hodgkin

FDA approved drugs:

(show all 7)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Bexxar 17 46 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa Approved June 2003
2
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
3
Mozobil 17 46 PLERIXAFOR Genzyme Approved December 2008
4
Rituxan 17 46 RITUXIMAB Biogen IDEC, Genentech Approved November 1997
5
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon Approved October 2008
6
Zevalin 17 46 IBRITUMOMAB TIUXETAN Biogen IDEC Approved February 2002
7
Zydelig 17 46 IDELALISIB Gilead Approved July 2014

Drugs for Lymphoma, Non-Hodgkin (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 725)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
5
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
8
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
9
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
10
Vidarabine Approved Phase 4,Phase 3,Phase 1,Phase 2 24356-66-9 32326 21704
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
12
Entecavir Approved, Investigational Phase 4,Phase 2 142217-69-4 153941
13
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 9015-68-3
14
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4291-63-8 20279
15
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
16
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
17
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
18
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
19
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
20
Thioguanine Approved Phase 4,Phase 3,Phase 1,Phase 2 154-42-7 2723601
21
Vindesine Approved Phase 4,Phase 3,Phase 2,Phase 1 59917-39-4, 53643-48-4 40839
22
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
23
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612
24
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
25
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
26
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1 173146-27-5
27
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 153559-49-0 82146
28
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
29
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 298-81-7 4114
30
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
31
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
32
Bleomycin Approved Phase 4,Phase 3,Phase 1,Phase 2 11056-06-7 5360373
33
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 147127-20-6 464205
34
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
35
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1 29767-20-2 34698
36
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-75-2 4033
37
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3375-50-6 598
38
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 130167-69-0
39
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
40
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
41
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
42
Aprepitant Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 170729-80-3 151165 6918365
43
Fosaprepitant Approved Phase 4,Phase 2,Phase 1,Early Phase 1 172673-20-0 219090
44
Lidocaine Approved, Vet_approved Phase 4,Phase 1,Phase 2 137-58-6 3676
45
Nitric Oxide Approved Phase 4 10102-43-9 145068
46
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
47
Prilocaine Approved Phase 4 721-50-6 4906
48
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
49
Infliximab Approved Phase 4 170277-31-3
50
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166

Interventional clinical trials:

(show top 50) (show all 3395)
id Name Status NCT ID Phase
1 Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. Unknown status NCT00429065 Phase 4
2 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4
3 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
4 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4
5 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
6 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4
7 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4
8 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4
9 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4
10 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4
11 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4
12 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4
13 Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation Completed NCT01339572 Phase 4
14 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4
15 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4
16 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
17 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4
18 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4
19 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
20 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
21 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4
22 Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands Completed NCT00731536 Phase 4
23 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4
24 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4
25 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4
26 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4
27 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4
28 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4
29 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4
30 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Recruiting NCT02996617 Phase 4
31 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4
32 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Recruiting NCT02585947 Phase 4
33 Low Grade Lymphoma Recruiting NCT01698866 Phase 4
34 ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors Recruiting NCT02938741 Phase 4
35 ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors Recruiting NCT02290132 Phase 4
36 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Recruiting NCT01746992 Phase 4
37 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Recruiting NCT02323659 Phase 4
38 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Recruiting NCT01804166 Phase 4
39 Treatment of Natural Killer/T Cell Lymphoma-I/II Recruiting NCT01501136 Phase 4
40 Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ Recruiting NCT01501149 Phase 4
41 Treatment of Diffuse Large B Cell Lymphoma Recruiting NCT01949818 Phase 4
42 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas Recruiting NCT03071822 Phase 4
43 A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Recruiting NCT03150602 Phase 4
44 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Recruiting NCT01569724 Phase 4
45 EDOCH Alternating With DHAP for New Diagnosed Younger MCL Recruiting NCT02858804 Phase 4
46 Reduced Chemotherapy in Low Risk DLBCL Recruiting NCT02752815 Phase 4
47 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4
48 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Active, not recruiting NCT01909934 Phase 4
49 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Active, not recruiting NCT01180049 Phase 4
50 An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Active, not recruiting NCT01833039 Phase 4

Search NIH Clinical Center for Lymphoma, Non-Hodgkin

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Non-Hodgkin cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoma, Non-Hodgkin

Genetic tests related to Lymphoma, Non-Hodgkin:

id Genetic test Affiliating Genes
1 Non-Hodgkin Lymphoma 29
2 Familial Non-Hodgkin Lymphoma 24
3 Lymphoma, Non-Hodgkin 24 PRF1

Anatomical Context for Lymphoma, Non-Hodgkin

MalaCards organs/tissues related to Lymphoma, Non-Hodgkin:

39
Lymph Node, B Cells, Bone, T Cells, Bone Marrow, Testes, Tonsil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin:
id Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Lymphoma, Non-Hodgkin

Articles related to Lymphoma, Non-Hodgkin:

id Title Authors Year
1
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. ( 25600050 )
2015
2
Social inequality and incidence of and survival from Hodgkin lymphoma, non-Hodgkin lymphoma and leukaemia in a population-based study in Denmark, 1994-2003. ( 18657412 )
2008

Variations for Lymphoma, Non-Hodgkin

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin:

66
id Symbol AA change Variation ID SNP ID
1 BRAF p.Gly469Ala VAR_018620 rs121913355
2 BRAF p.Gly469Arg VAR_018622 rs121913357
3 BRAF p.Asp594Gly VAR_018624 rs121913338
4 CASP10 p.Ala414Val VAR_037430 rs28936699

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin:

6 (show all 50)
id Gene Variation Type Significance SNP ID Assembly Location
1 RAD54B NM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser) single nucleotide variant Pathogenic rs114216685 GRCh37 Chromosome 8, 95403868: 95403868
2 RAD54L NM_001142548.1(RAD54L): c.1331T> A (p.Val444Glu) single nucleotide variant Pathogenic rs121908689 GRCh37 Chromosome 1, 46738430: 46738430
3 CASP10 NM_032977.3(CASP10): c.1241C> T (p.Ala414Val) single nucleotide variant Pathogenic rs28936699 GRCh37 Chromosome 2, 202074111: 202074111
4 CASP10 NM_032977.3(CASP10): c.769C> T (p.Gln257Ter) single nucleotide variant Pathogenic rs121909775 GRCh37 Chromosome 2, 202070652: 202070652
5 CASP10 NM_032977.3(CASP10): c.1042_1043insA (p.Gly348Glufs) insertion Pathogenic rs398122800 GRCh37 Chromosome 2, 202073912: 202073913
6 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
7 PRF1 NM_001083116.1(PRF1): c.1122G> A (p.Trp374Ter) single nucleotide variant Pathogenic rs104894176 GRCh37 Chromosome 10, 72358355: 72358355
8 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
9 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
10 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
11 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
12 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
13 MYD88 NM_001172567.1(MYD88): c.818T> C (p.Leu273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs387907272 GRCh37 Chromosome 3, 38182641: 38182641
14 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
15 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
16 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
17 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
18 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
19 MAP2K1 NM_002755.3(MAP2K1): c.171G> C (p.Lys57Asn) single nucleotide variant Likely pathogenic rs869025608 GRCh37 Chromosome 15, 66727455: 66727455
20 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
21 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
22 MYC NM_002467.4(MYC): c.218C> T (p.Thr73Ile) single nucleotide variant Likely pathogenic rs756091827 GRCh37 Chromosome 8, 128750681: 128750681
23 B2M NM_004048.2(B2M): c.3G> A (p.Met1Ile) single nucleotide variant Likely pathogenic rs1057519877 GRCh37 Chromosome 15, 45003747: 45003747
24 B2M NM_004048.2(B2M): c.1A> G (p.Met1Val) single nucleotide variant Likely pathogenic rs1023835002 GRCh37 Chromosome 15, 45003745: 45003745
25 B2M NM_004048.2(B2M): c.1A> T (p.Met1Leu) single nucleotide variant Likely pathogenic rs1023835002 GRCh37 Chromosome 15, 45003745: 45003745
26 B2M NM_004048.2(B2M): c.2T> C (p.Met1Thr) single nucleotide variant Likely pathogenic rs1057519879 GRCh37 Chromosome 15, 45003746: 45003746
27 B2M NM_004048.2(B2M): c.2T> G (p.Met1Arg) single nucleotide variant Likely pathogenic rs1057519879 GRCh37 Chromosome 15, 45003746: 45003746
28 EZH2 NM_004456.4(EZH2): c.1922A> T (p.Glu641Val) single nucleotide variant Likely pathogenic rs1057519894 GRCh37 Chromosome 7, 148508742: 148508742
29 EZH2 NM_004456.4(EZH2): c.1922A> C (p.Glu641Ala) single nucleotide variant Likely pathogenic rs1057519894 GRCh37 Chromosome 7, 148508742: 148508742
30 MAP2K1 NM_002755.3(MAP2K1): c.170A> C (p.Lys57Thr) single nucleotide variant Likely pathogenic rs1057519909 GRCh37 Chromosome 15, 66727454: 66727454
31 MYC NM_002467.4(MYC): c.217A> C (p.Thr73Pro) single nucleotide variant Likely pathogenic rs750664148 GRCh37 Chromosome 8, 128750680: 128750680
32 MYC NM_002467.4(MYC): c.173C> T (p.Pro58Leu) single nucleotide variant Likely pathogenic rs1057519918 GRCh37 Chromosome 8, 128750636: 128750636
33 PIK3CA NM_006218.3(PIK3CA): c.1031T> G (p.Val344Gly) single nucleotide variant Likely pathogenic rs1057519941 GRCh37 Chromosome 3, 178921549: 178921549
34 PIK3CA NM_006218.3(PIK3CA): c.1030G> A (p.Val344Met) single nucleotide variant Likely pathogenic rs1057519942 GRCh37 Chromosome 3, 178921548: 178921548
35 PIK3CA NM_006218.3(PIK3CA): c.1031T> C (p.Val344Ala) single nucleotide variant Likely pathogenic rs1057519941 GRCh37 Chromosome 3, 178921549: 178921549
36 RHOA NM_001664.3(RHOA): c.13C> T (p.Arg5Trp) single nucleotide variant Likely pathogenic rs1057519952 GRCh37 Chromosome 3, 49413010: 49413010
37 RHOA NM_001664.3(RHOA): c.14G> A (p.Arg5Gln) single nucleotide variant Likely pathogenic rs1057519953 GRCh37 Chromosome 3, 49413009: 49413009
38 RHOA NM_001664.3(RHOA): c.14G> T (p.Arg5Leu) single nucleotide variant Likely pathogenic rs1057519953 GRCh37 Chromosome 3, 49413009: 49413009
39 RHOA NM_001664.3(RHOA): c.125A> G (p.Tyr42Cys) single nucleotide variant Likely pathogenic rs1057519954 GRCh37 Chromosome 3, 49412898: 49412898
40 RHOA NM_001664.3(RHOA): c.125A> C (p.Tyr42Ser) single nucleotide variant Likely pathogenic rs1057519954 GRCh37 Chromosome 3, 49412898: 49412898
41 RHOA NM_001664.3(RHOA): c.125A> T (p.Tyr42Phe) single nucleotide variant Likely pathogenic rs1057519954 GRCh37 Chromosome 3, 49412898: 49412898
42 TP53 NM_001126112.2(TP53): c.845G> C (p.Arg282Pro) single nucleotide variant Likely pathogenic rs730882008 GRCh37 Chromosome 17, 7577093: 7577093
43 TP53 NM_001126117.1(TP53): c.326C> A (p.Ser109Tyr) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
44 TP53 NM_001126115.1(TP53): c.325T> C (p.Ser109Pro) single nucleotide variant Likely pathogenic rs1057520002 GRCh37 Chromosome 17, 7577560: 7577560
45 TP53 NM_001126114.2(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 GRCh37 Chromosome 17, 7577560: 7577560
46 TP53 NM_001126118.1(TP53): c.497A> G (p.Tyr166Cys) single nucleotide variant Likely pathogenic rs1057520007 GRCh37 Chromosome 17, 7578235: 7578235
47 TP53 NM_001126117.1(TP53): c.218A> T (p.Tyr73Phe) single nucleotide variant Likely pathogenic rs1057520007 GRCh37 Chromosome 17, 7578235: 7578235
48 TP53 NM_001126118.1(TP53): c.497A> C (p.Tyr166Ser) single nucleotide variant Likely pathogenic rs1057520007 GRCh37 Chromosome 17, 7578235: 7578235
49 TP53 NM_001126113.2(TP53): c.613T> A (p.Tyr205Asn) single nucleotide variant Likely pathogenic rs1057520008 GRCh37 Chromosome 17, 7578236: 7578236
50 TP53 NM_000546.5(TP53): c.613T> C (p.Tyr205His) single nucleotide variant Likely pathogenic rs1057520008 GRCh37 Chromosome 17, 7578236: 7578236

Cosmic variations for Lymphoma, Non-Hodgkin:

9 (show all 16)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 7
2 COSM44571 TP53 haematopoietic and lymphoid tissue,l